Ares Capital Corporation (ARCC) Stock Price & Analysis
Ares Capital Corporation (ARCC) closed at USD 18.79 on Thursday, October 22, 2026, up 2.12% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 18.4; the Oct 22, 2026 session ranged USD 18.31–18.81 on volume of 3,965,517 shares. Market capitalization is $13.49B, with a 52-week range of USD 17.4–21.14 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ARCC.md
Key facts (ARCC)
- Valuation: P/E 14.1x (avg 9.2x at the last 3 fiscal year-ends), net debt $15.4B.
- Analysts: Buy (mean 1.93 on a 1–5 scale) (14 analysts), mean target USD 20.77 (range 19–23).
- Total return with dividends: 1Y +4.1% vs S&P 500 +14.9%; 5Y +42.5% vs S&P 500 +80.3%.
- Next earnings: 2026-10-27, EPS estimate USD 0.48, revenue estimate $776M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ARCC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Net income | $1.57B | $600M | $1.52B | $1.52B | $1.30B | $960M |
| EPS (diluted) | $3.51 | $1.19 | $2.68 | $2.44 | $1.86 | — |
| Cash + short-term investments | $372M | $303M | $535M | $635M | $638M | — |
| Total debt | $11.0B | $12.2B | $11.9B | $13.7B | $16.0B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ARCC)
P/E 14.1x · P/B 1.0x · Earnings yield 7.12% · Dividend yield (paid, TTM) 9.85% · Net debt $15.4B · EV $28.9B
P/E at fiscal year-ends: Dec 2025 10.9x, Dec 2024 9.0x, Dec 2023 7.6x.
Analysts (ARCC)
Consensus Buy (mean 1.93 on a 1–5 scale), 14 analysts; mean target USD 20.77 (low 19, high 23).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-01 | UBS | Target raised | Neutral | $19 → $21 |
| 2026-07-30 | Truist Securities | Target lowered | Buy | $22 → $21 |
| 2026-07-30 | Keefe, Bruyette & Woods | Target lowered | Outperform | $21 → $20 |
| 2026-07-02 | JP Morgan | Target lowered | Overweight | $19 → $18.5 |
Total return (dividends reinvested) (ARCC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +4.1% | +42.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +4.2% | +7.3% |
| Volatility (annualized) | 18.7% | 18.3% |
| Max drawdown | -14.6% (Jan 2026→Mar 2026) | -19.2% (Jul 2025→Mar 2026) |
Companies that name ARCC in their SEC reports
| Relationship to ARCC | Company | Filing | Sentence |
|---|---|---|---|
| partner | Evolent Health, Inc. (EVH) | 10-K Feb 25, 2026 | “On December 31, 2025, using proceeds from the sale of Evolent Care Partners, the Company repaid $82.8 million of principal on its Ares First Lien Term Loan Facility and recorded a loss of $3.9 million in loss on extinguishment and repayment of debt, net, comprised of $0.8 million of contractual prepayment penalty in accordance with the Credit Agreement and $3.1 million of acceleration of amortization of deferred f…” |
| partner | Tempus AI, Inc. (TEM) | 10-K Feb 24, 2026 | “We are party to a credit agreement with Ares Capital Corporation, under which we have $206.0 million outstanding in term loans and $100.0 million outstanding in revolving credit facility as of December 31, 2025.” |
| partner | Moderna, Inc. (MRNA) | 10-K Feb 20, 2026 | “A failure to comply with the covenants in our credit agreement with lenders led by Ares Capital Corporation, as administrative agent, could result in an event of default, which, if not cured or waived, could have a material, adverse effect on our business, financial condition, and results of operations.” |
ARCC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.48 | $0.48 | -1.0% | $776.1M | 14 |
| Next quarter (ends Dec 2026) | $0.48 | $0.48 | +0.6% | $788.9M | 14 |
| Current fiscal year (ends Dec 2026) | $1.91 | $1.92 | -0.7% | $3.09B | 14 |
| Next fiscal year (ends Dec 2027) | $1.94 | $1.92 | +0.8% | $3.20B | 14 |
Key Statistics (as of October 23, 2026 at 10:11 UTC)
| Price | USD 18.79 |
|---|---|
| Change | ▲ 2.12% (up) |
| Previous Close | USD 18.4 |
| Open | USD 18.33 |
| Day Range | USD 18.31 – 18.81 |
| 52-Week Range | USD 17.4 – 21.14 |
| Volume | 3,965,517 shares |
| Market Cap | $13.49B |
| Exchange | NMS |
Technical Analysis (ARCC)
Nexqual's technical model rates ARCC "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 10:11 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.31 (neutral) |
| vs SMA50 | Below (USD 19.35) |
| MACD | -0.21 (negative) |
Analyst Ratings (ARCC)
Wall Street analysts rate ARCC "Buy" based on 14 analysts, with a mean price target of USD 20.77 (range USD 19–23), per Nexqual as of October 23, 2026 at 10:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 20.77 |
| High Target | USD 23 |
| Low Target | USD 19 |
| Buy / Hold / Sell | 11 / 3 / 0 |
Earnings (ARCC)
| Next Earnings Date | 2026-10-27 |
|---|---|
| EPS Estimate | USD 0.48 |
| Revenue Estimate | $776.12M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.47 vs est 0.47 ▼ miss |
| 2026-03-31 | USD 0.47 vs est 0.48 ▼ miss |
| 2025-12-31 | USD 0.5 vs est 0.5 ▲ beat |
| 2025-09-30 | USD 0.5 vs est 0.5 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financials & Fundamentals (ARCC)
| Total Revenue | $3.11B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +3.10% |
| Gross Margin | +100.00% |
| Operating Margin | +75.65% |
| Profit Margin | +30.91% |
| ROE | +6.88% |
| Debt / Equity | 1.14 |
| Current Ratio | 0.61 |
| Total Cash | $398.00M |
| Total Debt | $15.85B |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financial Health Score (ARCC)
Nexqual rates Ares Capital Corporation's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:11 UTC.
| Growth | Mixed — Revenue +2.1% YoY (annual), slow |
|---|---|
| Profitability | Strong — Operating margin 76% |
| Balance Sheet | Weak — $383M cash and investments vs $15.8B debt (Jun 2026, SEC) |
| Cash Flow | Weak — Operating cash flow -$1.72B (FY ended Dec 2025, 10-K) |
| Efficiency | Mixed — ROE 7%, ROA 4.9% |
Ownership (ARCC)
| Insider Ownership | +0.56% |
|---|---|
| Institutional Ownership | +36.12% |
| Shares Outstanding | 718.02M |
| Short % of Float | +5.68% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Leadership (ARCC)
Ares Capital Corporation is led by Kort Schnabel, CEO & Co-Head of U.S. Direct Lending, per Nexqual as of October 23, 2026 at 10:11 UTC.
| CEO & Co-Head of U.S. Direct Lending | Kort Schnabel |
|---|---|
| Co-Chairman, Partner & Co-Head of Ares Credit Group | Mitchell Scott Goldstein |
| Co-Chairman of Board of Directors & Co-Head of Ares Credit Group | Michael Lewis Smith |
| Executive VP & Director | Michael J. Arougheti |
| President & Co-Head of U.S. Direct Lending | James Miller |
Major Backers & Investors (ARCC)
Notable institutional backers of Ares Capital Corporation include Morgan Stanley, UBS Group AG, Van Eck Associates Corporation, according to Nexqual as of October 23, 2026 at 10:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 2.37% |
| UBS Group AG | 1.92% |
| Van Eck Associates Corporation | 1.85% |
| VanEck ETF Trust-VanEck BDC Income ETF | 1.52% |
| STRS Ohio | 1.48% |
| Bank of America Corporation | 1.24% |
| JPMorgan | 1.09% |
| Generali Asset Management Spa Sgr | 1.05% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Legal & General Group PLC | 0.91% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CG | The Carlyle Group Inc. | USD 39.2 | ▲ 5.18% |
| SEIC | SEI Investments Company | USD 104.5 | ▼ 3.62% |
| IVZ | Invesco Ltd | USD 28.79 | ▼ 1.57% |
| OWL | Blue Owl Capital Inc. | USD 9.71 | ▲ 5.89% |
| PHYS | "Sprott Physical Gold Trust" | USD 30.39 | ▼ 2.72% |
| EQH | Equitable Holdings, Inc. | USD 55.04 | ▲ 1.23% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt